|
|
|
|
|
|
|
|
|
|
|
|
|
16.11.26 - 07:01
|
Roche′s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy (GlobeNewswire EN)
|
|
|
Basel, 16 November 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria. Gazyva/Gazyvaro becomes the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy Designation. A chronic autoimmune disease that can lead to kidney failure, pMN carries a substantial human and economic burden for patients, caregivers and health systems alike.1,2 Proteinuria is a key indicator of kidney damage characterised by high urine protein levels....
|
|
|
13.11.26 - 19:09
|
Moog Inc. to Announce Fiscal 2026 Year-End Results on November 20, 2026 (Business Wire)
|
|
|
EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. (NYSE: MOG.A and MOG.B) will release its fiscal 2026 fourth quarter and full year financial results on Friday, November 20, 2026.
Pat Roche, CEO, and Jennifer Walter, CFO, will host a conference call on November 20 at 10:00 a.m. ET. Listeners can access the live webcast or a replay of the call at http://www.moog.com/investors/events-presentations/. Supplemental slides will be available on the Company's website, and the replay will remain archived for 45 days.
About Moog Inc.
Moog is a worldwide designer, manufacturer, and systems integrator of high-performance precision motion and fluid controls and control systems. Moog's high-performance systems control military and commercial aircraft, satellites, and space vehicles, launch vehicles, defense systems, missiles, automated industrial machinery, marine, and medical equipment. Additional information about the Company can be found at www.moog.com. Contacts
Aaron Astrachan
Director, Investor Relations
716.687.4225...
|
|
|
|
|
|
|
|
|
13.11.26 - 12:31
|
CHMP recommends EU approval of Roche′s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE) (GlobeNewswire EN)
|
|
|
Basel, 13 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gazyva®/Gazyvaro® (obinutuzumab) as an add-on therapy for the treatment of adult patients with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus (SLE) despite standard therapy. A final decision from the European Commission is expected in the near future. In addition, the US Food and Drug Administration (FDA) accepted Roche's supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro in SLE earlier this year. This recommendation builds on a growing list of approvals across immune-mediated diseases for Gazyva/Gazyvaro, including active lupus nephritis (LN) in more than 65 countries and idiopathic nephrotic syndrome (INS) in the US.4...
|
|
|
|
|
|
|
|
|
|
|
10.11.26 - 07:01
|
Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer′s disease portfolio at CTAD 2026 (GlobeNewswire EN)
|
|
|
Basel, 10 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data across its pharmaceuticals and diagnostics portfolios at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Congress, taking place in Boston, MA, from 16–19 November 2026. Across 16 accepted abstracts, including two scientific symposia and two oral presentations, Roche will highlight its differentiated approach to neurodegeneration: uniting high-accuracy diagnostic testing with targeted investigational therapeutics to address the disease across its continuum....
|
|
|
|
|
04.11.26 - 11:15
|
Roche Hold (DPA-AFX)
|
|
|
HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Roche nach einem Treffen mit Finanzvorstand Alan Hippe auf "Hold" mit einem Kursziel von 350 Franken belassen. Der Manager des Pharmakonzerns habe sich sehr zuversichtlich gezeigt, ......
|
|
|
|
|
02.11.26 - 17:01
|
Roche erhält FDA-Zulassung für Cobas-Atemwegstest (DPA-AFX)
|
|
|
BASEL (dpa-AFX) - Roche hat von der US-Gesundheitsbehörde FDA für den Cobas-Atemwegstest "Cobas Eplex Respiratory Pathogen Panel 3 (RP3)" die Zulassung erhalten. Der Test kann laut der Mitteilung vom Montag anhand einer ......
|
|